With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit.  | Rocket has announced that the FDA signed off on an accelerated approval for its ...

All six participants tolerated surgical and intra-cochlear SENS-501 administration well, with no serious adverse events reported.

US Food and Drug Administration (FDA) officials credited recent advancements in regulatory science and flexibilities with ...

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Ocugen’s updated fair value estimate has shifted from US$10.36 to US$11.57, putting recent analyst work into a slightly higher price target range. Analysts are tying this move to fresh research around ...

Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and regulatory steps clustered into 2026 and early 2027. The s ...

Positive clinical results for Ocugen's lead gene therapy candidate have failed to translate into market gains, highlighting the stark divide between scientific progress and investor sentiment in the ...

What happened next may become the most important medical story of the decade. In just six months, a team at Children’s ...

Gene therapy approaches include gene replacement, suppression, and editing, each matched to specific genetic mechanisms in hereditary hearing loss. Preclinical studies in rodent models show promise, ...

What Is Waskyra, and Why Does It Matter? Waskyra (etuvetidigene autotemcel) is a new gene therapy approved to treat Wiskott-Aldrich syndrome (WAS), a rare inherited condition that affects the immune ...

Ocugen (OCGN) has drawn investor attention after recent trading data highlighted sharp swings in shorter term returns, with the share price flat over the past day but showing larger moves over the ...